Bring the potential of ROZLYTREK® to life

ROZLYTREK demonstrates clinically meaningful and durable responses in NTRK fusion+ tumours and ROS1+ NSCLC, irrespective of baseline CNS metastases1

hero-mobile-text.jpg

ROZLYTREK demonstrates clinically meaningful and durable responses in NTRK fusion+ tumours and ROS1+ NSCLC, irrespective of baseline CNS metastases1

ROZLYTREK is a tyrosine kinase inhibitor with a well-tolerated and consistent safety profile in both adult and paediatric patients1,2

 

Therapeutic indications1

ROZLYTREK as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older, with solid tumours, expressing a neurotrophic tyrosine kinase (NTRK) gene fusion: 

• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and

• who have not received a prior NTRK inhibitor,

• who have no satisfactory treatment options.

 

ROZLYTREK as monotherapy is indicated for the treatment of adult patients with c-ros oncogene 1 (ROS1)-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.

 

icon-what-is-roz.png

What is ROZLYTREK?

Discover ROZLYTREK

mode of action

ICON_ROS1_NSCLC.png

ROS1+ NSCLC

Learn more about clinical
trials and efficacy

ICON_NTRK fusion.png

NTRK fusion+ solid tumours

Learn more about clinical trials

and efficacy

ICON_safety_overview.png

ROZLYTREK safety overview

Find out about

ROZLYTREK safety

ICON_prescribing.png

Prescribing ROZLYTREK

ROZLYTREK offers convenient
once-daily dosing

ICON_patient-benefits.png

Patient benefits

Find out how ROZLYTREK

helps patients

ICON_gene-fusion.png

Gene fusion detection

Learn more about actionable
fusions and how to

identify them

ICON_disease-support.png

Disease support

Help patients understand ROS1 and
NTRK fusion+ cancer

Coming soon

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.

Footnotes

CNS, central nervous system; NSCLC, non-small cell lung cancer; NTRK, neurotrophic tyrosine receptor kinase; ROS1, c-ros oncogene 1.

 

References

  1. ROZLYTREK Summary of Product Characteristics, 2020.
  2. Patel M, et al. Ann Oncol 2020;31(Suppl 3):232–233.